AstraZeneca has completed a clearout (PDF) of its midphase pipeline, dumping a clutch of cancer, diabetes and cardiovascular disease drugs it picked up in deals including its $1 billion takeover of Ardea Biosciences.
Grunenthal GmbH's Duzallo (allopurinol / lesinurad) Receives Approval in Europe
AstraZeneca paid $1.3 billion to buy the experimental gout drug lesinurad. They handed over US rights to Ironwood $IRWD for much, much less two years ago — after it was approved on mixed efficacy and safety data.
Zurampic, a drug AstraZeneca once laid out more than $1 billion to get its hands on, has wound up on the scrap heap.
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).
Ironwood $IRWD is splitting up its business into two distinct halves, spinning out a pipeline of early- and mid-stage drugs into a separate, publicly traded biotech company while keeping its marketed products and related development projects in house at a scaled down, and more profitable, mother company.
The US FDA has approved Ironwood Pharma's combination gout therapy Duzallo, but with a warning that it can cause serious kidney failure.
Ironwood Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its oral drug to treat a condition associated with gout.
Cost regulators for the NHS in England and Wales have published draft guidelines barring adults with gout from routine access to Gruenenthal’s Zurampic-based therapy for treating hyperuricaemia.
The Ministry of Health and Prevention has warned against taking one lot of JB504 of Brilinta 90 mg tablets BRILINTA, which is indicated to reduce the rate of CV death, heart attacks and strokes in patients with acute coronary syndrome (ACS) or a history of heart attack.